16 ML bevacizumab-nwgd 25 MG/ML Injection [Jobevne]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
16 ML bevacizumab-nwgd 25 MG/ML Injection [Jobevne]
25 MG/ML · Injection · injection
A form of bevacizumab-nwgd →
16 ML bevacizumab-nwgd 25 MG/ML Injection [Jobevne] — VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors. Strength, form, class, interactions & more.
![16 ML bevacizumab-nwgd 25 MG/ML Injection [Jobevne]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70ab1de6-fb68-aee4-a6cb-f9a0f146687f&name=Image-10.jpg)
Active ingredient
Classification
VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsVascular Endothelial Growth Factor Inhibitor
Drug interactions
Bevacizumab does not have a clinically meaningful effect on the pharmacokinetics of certain drugs, but there may be variations in drug exposure when combined with paclitaxel and carboplatin.
- unknownirinotecan — No clinically meaningful effect on pharmacokinetics observed.
- unknowninterferon alfa — No clinically meaningful effect on pharmacokinetics observed.
- unknowncarboplatin — No clinically meaningful effect on pharmacokinetics observed.
- moderatepaclitaxel — No clinically meaningful effect on pharmacokinetics observed, but lower exposure noted after treatment.
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication